ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.56 +0.42%

+$0.04 today

Market cap
$3.01B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.17M

Average 7.07M

ADMA Net Income

Bottom-line profit after all expenses, interest, and taxes.

ADMA Biologics, Inc.NASDAQ: ADMA

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $37.82M rose 10.5% year over year, ahead of the -19.1% change in trailing-twelve-month net income. Sequentially, it fell 16.6% from the prior quarter.

Context

  • Net income amounted to 28.8% of revenue in FY2025, down 17.6 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of $201.43M (+37.1%) for the fiscal year ending Dec 2026, a step up from the -25.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$37.82M-16.6% QoQ
Last fiscal yearDec 2025
$146.93M-25.7% YoY
LTMJun 2026
$168.96M-19.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.5%+21.9%+11.4 pp
1 year-25.7%+37.1%+62.8 pp
3-year CAGR—+22.7%—
5-year CAGR+22.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
146.93M USD
Year-over-year change
-25.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ADMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -19.1% is the lowest of 4, against a peer median of +52.1%.
  • Net income amounts to 33.0% of revenue for ADMA, versus a peer median of 84.0%.
ADMA Competitors
Net Income for ADMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GRFSGrifols, S.A.LTM Jun 2026€452.49M EUR+52.1%+27.8%6.1%
ADMAADMA Biologics, Inc.LTM Jun 2026$168.96M USD-19.1%—33.0%
ABUSArbutus Biopharma CorporationLTM Mar 2026$160.72M USD+309.9%—84.0%
IVVDInvivyd, Inc.LTM Mar 2026-$77.6M USD+45.6%—138.9%
Peer median (excluding ADMA) —+52.1%+27.8%84.0%

Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue80.94M154.08M258.22M426.45M510.17M
Cost of Revenue79.77M118.82M169.27M206.9M217.41M
Gross Profit1.17M35.27M88.94M219.55M292.77M
Gross Margin1.4%22.9%34.4%51.5%57.4%
Research & Development3.65M3.61M3.3M1.81M4.76M
Selling, General & Admin42.9M52.46M59.02M74.12M91.58M
Operating Expenses59.55M74.63M67.31M80.57M101.32M
Depreciation & Amortization5.5M7.11M8.33M8.05M8.1M
EBITDA(53.1M)(39.51M)5.12M147.69M197.86M
EBITDA Margin-65.6%-25.6%2.0%34.6%38.8%
Operating Income(58.37M)(39.37M)21.63M138.98M191.44M
Operating Margin-72.1%-25.5%8.4%32.6%37.5%
Interest Income34.53K44.83K1.62M2.1M1.87M
Interest Expense13.06M19.28M25.03M13.93M7.11M
Other Income / Expenses(13.27M)(26.54M)(49.87M)(13.27M)(8.79M)
Income Before Tax(71.65M)(65.9M)(28.24M)125.71M182.66M
Pre-Tax Margin-88.5%-42.8%-10.9%29.5%35.8%
Income Tax Expense000(71.96M)35.73M
Net Income(71.65M)(65.9M)(28.24M)197.67M146.93M
Net Margin-88.5%-42.8%-10.9%46.4%28.8%
EPS (Basic)(0.61)(0.43)(0.13)0.850.62
EPS (Diluted)(0.61)(0.43)(0.13)0.810.60
Weighted Avg Shares139.58M197.87M223.98M233.08M238.3M
Weighted Avg Shares (Diluted)139.58M197.87M223.98M243.34M244.9M

ADMA Biologics, Inc.

NASDAQ:ADMA

Intrinsic Alpha fair value

Locked

Current Price

$13.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.